References

• 1. Kashani K, Rosner MH, Ostermann M. Creatinine: from physiology to clinical application. Eur J Intern Med. 2020;72:9-14. google scholar
• 2. Cavalcanti E, Barchiesi V, Cerasuolo D, et al. Correlations of serum cystatin C with glomerular filtration rate in patients receiving platinum-based chemotherapy. Anal Cell Pathol (Amst). 2016;2016:4918325 google scholar
• 3. Janowitz T, Williams EH, Marshall A, et al. New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol. 2017;35:2798-2805. google scholar
• 4- Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520-528. google scholar
• 5. Konigsbrugge O, Lotsch F, Zielinski C, Pabinger I, Ay C. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res. 2014;134:44-49. google scholar
• 6. Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin. 2021 Jan;71(1):47-77. doi: 10.3322/caac.21636. Epub 2020 Aug 27. PMID: 32853404. google scholar
• 7. US Renal Data System (USRDS). Chapter 5: Acute kidney injury. In: USRDS, ed. 2014 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Vol. 1. National Institutes of Health, National Institute of Diyabetes and Digestive and Kidney Diseases. USRDS; 2014:37-45. Accessed March 24, 2020. usrds.org/2014/view/v1_05.aspx google scholar
• 8. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sorensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22:399-406. google scholar
• 9. Liborio AB, Abreu KL, Silva GB Jr, et al. Predicting hospital mortality in critically ill cancer patients ac-cording to acute kidney injury severity. Oncology. 2011;80(3-4):160-166. google scholar
• 10. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-1854. google scholar
• 11. Criscuolo M, Fianchi L, Dragonetti G, Pagano L. Tumor lysis syndrome: review of pathogenesis, risk fac-tors, and management of a medical emergency. Expert Rev Hematol. 2016;9:197-208 google scholar
• 12. Wilson FP, Berns JS. Onconephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012;7:1730-1739. google scholar
• 13. Alakel N, Middeke JM, Schetelig J, Bornhauser M. Prevention and treatment of tumor lysis syndrome and the efficacy and role of rasburicase. Onco Targets Ther. 2017;10:597-605. google scholar
• 14. Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol. 2007;178:178-183. google scholar
• 15. Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015;11:354-370. google scholar
• 16. Skinner R. Strategies to prevent nephrotoxicity of anticancer drugs. Current Opinion Oncol. 1995;7:310-315. google scholar
• 17. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, patho-biology, and prevention/therapy. Semin Nephrol. 2010;30:570-581. google scholar
• 18. Wall SM, Johansen MJ, Molony DA, DuBose TD, Jaffe N, Madden T. Effective clearance of methotrexate using highflux hemodialysis membranes. Am J Kidney Dis. 1996;28:846-854. google scholar
• 19. Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34:427-439. google scholar
• 20. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015;10:1291-1299. google scholar
• 21. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology. 2002;16:11-20. google scholar
• 22. Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020;97:62-74. google scholar
• 23. Saly D, Perazella MA. The adverse effects of cancer immunotherapies. J Onco-Nephrol. 2018;2:56-68. google scholar
• 24. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122:322-328. google scholar
• 25. Perazella MA, Izzedine H. ALK inhibitors. Crizotinib: renal safety evaluation. J Onco-Nephrol. 2017;1:49-56. google scholar
• 26. Schmid M, Abd-El-Barr AE, Gandaglia G, et al. Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014;32:1259-1266 google scholar
• 27. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992;89: 630-639. google scholar
• 28. Leung N, Behrens J. Current approach to diagnosis and management of acute renal failure in myeloma patients. Adv Chronic Kidney Dis. 2012;19:297-302. google scholar
• 29. Dimopoulos MA, Roussou M, Gavriatropoulou M, et al. Bortezomibbased triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499-502. google scholar
• 30. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28:4635-4641. google scholar
• 31. Glavey SV, Gertz MA, Dispenzieri A, et al. Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant. 2013;48: 1543-1547. google scholar
• 32. Bridoux F, Carron PL, Pegourie B, et al; MYRE Study Group. Effect of high-cutoff hemodialysis vs con-ventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA. 2017;318:2099-2110. google scholar
• 33. Madore F. Plasmapheresis in cast nephropathy: yes or no? Curr Opin Nephrol Hypertens. 2015;24:177-182. google scholar
• 34. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120:4292-4295. google scholar
• 35. Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84:34-44. google scholar
• 36. Heaf JG, Hansen A, Laier GH. Quantification of cancer risk in glomerulonephritis. BMC Nephrol. 2018;19:27. google scholar
• 37. Beck LH Jr. PLA2R and THSD7A: disparate paths to the same disease? J Am Soc Nephrol. 2017;28:2579-2589. google scholar
• 38. Baldeo C, Ali R, Hritani A, Poenariu A. ANCA-negative pauci-immune crescentic glomerulonephritis linked with nonsmall cell carcinoma of the lung. Case Rep Nephrol Dial. 2015;5:168-172. google scholar
• 39. Mallouk A, Pham PTT, Pham PCT. Concurrent FSGS and Hodgkin’s lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol. 2006;10: 284-289. google scholar
• 40. Au WY, Chan KW, Lui SL, Lam CCK, Kwong YL. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis. 1999;34:889-893. google scholar
• 41. Uppal NN, Monga D, Vernace MA, et al. Kidney diseases associated with Waldenstrom macroglobulinemia. Nephrol Dial Transplant. 2019;34:1644-1652. google scholar
• 42. Parikh CR, Yarlagadda SG, Storer B, Sorror M, Storb R, Sandmaier B. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:309-315. google scholar
• 43. Jo T, Arai Y, Kondo T, et al. Chronic kidney disease in long-term survivors after allogeneic hematopoie-tic stem cell transplantation: retrospective analysis at a single institute. Biol Blood Marrow Transplant. 2017;23:2159-2165. google scholar
• 44. Kemper MJ, Gungor T, Halter J, Schanz U, Neuhaus TJ. Favorable long-term outcome of nephrotic synd-rome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol. 2007;67:5-1. google scholar
• 45. Hamawi K, De Magalhaes-Silverman M, Bertolatus JA. Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant. 2003;3:301-305. google scholar
• 46. Cohen EP, Krzesinski JM, Launay-Vacher V, Sprangers B. Onco-nephrology: Core Curriculum 2015. Am J Kidney Dis. 2015 Nov;66(5):869-83. doi: 10.1053/j.ajkd.2015.04.042. Epub 2015 Jun 6. google scholar
• 47. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012;59:222-228. google scholar
• 48. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97-110. google scholar
• 49. Berardi R, Mastroianni C, Lo Russo G, et al. Syndrome of inappropriate anti-diuretic hormo-ne secretion in cancer patients: results of the first multicenter Italian study. Ther Adv Med Oncol. 2019;11:1758835919877725. google scholar
• 50. Refardt J, Imber C,Sailer C, et al. A Randomized Trial of Empaglifozin tı Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. JASN 31:615-624,2020 google scholar
• 51. Edate S, Albanese A. Management of electrolyte and fluid disorders after brain surgery for pituitary/supra-sellar tumours. Horm Res Paediatr. 2015;83:293-301. google scholar
• 52. Chauhan K, Pattharanitima P, Patel N, et al. Rate of correction of hypernatremia and health outcomes in critically ill patients. Clin J Am Soc Nephrol. 2019;14:656-663. google scholar
• 53. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med. 1980;93:269-272. google scholar
• 54. Bover J, Bailone L, Lopez-Baez V, Benito S, Ciceri P, Galassi A, Cozzolino M. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol. 2017;30:677-687. google scholar
• 55. Sturniolo G, Lo Schiavo MG, Tonante A, D’Alia C, Bonanno L. Hypocalcemia and hypoparathyroidism after total thyroidectomy: a clinical biological study and surgical considerations. Int J Surg Investig. 2000;2:99-105 google scholar
• 56. Khan MI, Dellinger RP, Waguespack SG. Electrolyte disturbances in critically ill cancer patients: an endoc-rine perspective. J Intensive Care Med. 2018;33:147-158. google scholar
• 57. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unste-adiness, and attention deficits. Am J Med. 2006;119:71 google scholar
• 58. Yoshida T, Taguchi D, Fukuda K, et al. Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution. Int J Clin Oncol. 2017;22:244-249. google scholar